Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio EssenceBIOE 35 EV-to-EBIT is 7.37 as of Sep. 21, 2026. GuruFocus rates BIOE with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 682 Drug Manufacturers companies, Bio Essence ranks better than 80.65% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bio Essence's Enterprise Value for the quarter that ended in Jun. 2026 was $15.32 Mil.
Bio Essence's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Essence EV-to-EBIT Related Terms
Bio Essence EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bio Essence's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bio Essence's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Essence EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bio Essence's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bio Essence's EV-to-EBIT falls into.
Bio Essence's current Enterprise Value is $11.36 Mil.
Bio Essence's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Essence (BIOE) has a EV-to-EBIT of 7.37 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bio Essence and its competitors. According to the industry distribution chart, Bio Essence ranks #132 out of 682 companies in the Drug Manufacturers industry, placing it in the top 19.4%.
Is Bio Essence's EV-to-EBIT too high?
Bio Essence's current EV-to-EBIT is 7.37. The Drug Manufacturers industry median EV-to-EBIT is 16.08. Bio Essence's value of 7.37 is 54.2% below this industry median. Based on the distribution chart, Bio Essence ranks #132 out of 682 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Essence has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Bio Essence's EV-to-EBIT compare to INM and SNOA?
According to the Drug Manufacturers industry distribution chart, Bio Essence ranks #132 out of 682 companies for EV-to-EBIT. This places Bio Essence in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 16.08. Bio Essence's value of 7.37 is 54.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.08, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Essence's current EV-to-EBIT of 7.37 is 54.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bio Essence and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Essence's current EV-to-EBIT is 7.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Essence stock overvalued right now?
Bio Essence (BIOE) has a current EV-to-EBIT of 7.37. The current EV-to-EBIT is 7.37 and 54.2% below the Drug Manufacturers industry median of 16.08. Bio Essence's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bio Essence (BIOE), the current EV-to-EBIT is 7.37 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offered specially formulated dietary supplements and medical food. The Company operates in one business and industry segment: the manufacture / OEM and sale of health supplement products. The group's products are RED Yeast Rice Plus, Regenva, MediDrink, and Nufargo.
35GF Score
Get the complete analysis for BIOE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOE has been successfully added to your 
